Efficacy of subcutaneous dupilumab a human anti-interleukin-4 receptor alpha monoclonal antibody for moderate-to-severe uncontrolled asthmatics.

For moderate-to-severe persistent asthmatics that remain symptomatic despite their anti-inflammatory high dose inhaled corticosteroid treatment with inhaled long-acting beta2-agonist bronchodilator, the addition of subcutaneous Dupilumab, a fully human anti-interleukin-4 receptor alpha monoclonal antibody that blocks both interleukin-4 and interleukin-13 signaling, may provide additional efficacy in sub optimally controlled moderate-to-severe persistent asthmatics.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: P209 Source Type: research